US healthcare market entry, planned by someone who has run US healthcare operations.
Most UK healthcare companies do not fail in the US because the strategy was wrong. They fail because the operating model, the buyer and the sequencing were never tested against how American healthcare actually pays, licenses and delivers care. Clarendum works on that gap.
The differentiator: operator-led, not research-led
A market entry report tells you the market is large. An operator tells you what it will take to serve it. Clarendum is led by Ian McPhee, formerly Vice President of Operations at Optum Behavioural Care, part of United Health Group, where he led operations across a national network of 236 clinics and telehealth services serving patients in all 50 states. That means the entry plan is written with credentialling queues, clinician supply, utilisation targets and access pathways already in view.
The work is deliberately senior and hands-on. You deal directly with Ian throughout — there is no junior team producing a deck it has never had to implement.
What we work through
Route to revenue: payer, employer or cash-pay
We test each route against your model, not in the abstract: what a payer would need to contract you, whether an employer or benefits route is faster, and what a cash-pay proposition would have to be worth to a patient. The output is a ranked route with the operational burden of each made explicit — including the claims, coding and denials capability payer routes require.
Buyer and budget-holder mapping
Who signs, who blocks, and who is measured on the problem you solve. In US healthcare these are frequently three different people inside the same organisation. We map the buying unit, the evidence each member needs, and the procurement cycle length so pipeline forecasts are grounded.
State and regulatory complexity, strategically
Not legal advice — a strategic view of where regulatory load sits and how it shapes sequencing: clinician licensure and credentialling, telehealth practice requirements, payer enrolment lead times, and which state clusters give you the largest addressable population for the least incremental operational cost.
Operating model and workforce
Clinical supervision, rota and coverage design, capacity planning, technology and data flows, and the back-office functions that multi-state operations demand. This is where UK models most often need redesign rather than translation.
Patient access and conversion
US patients and referrers behave differently at the front door. Intake, eligibility and benefits checks, scheduling and follow-up all sit on the revenue line. We design the access pathway before volume arrives, not after it disappoints.
Commercial validation and sequencing
A staged plan with decision gates: what must be true before the next tranche of spend is released, which pilots count as evidence, and what the first hundred days after commitment contains.
If you want to test where your own plan sits before we speak, the UK to US expansion readiness scorecard scores the same eight dimensions we work through here.
Regulatory, tax and corporate structuring specifics should be confirmed with qualified US legal and tax advisers. Clarendum's role is the commercial and operational decision around them.
Five UK assumptions that fail in the US
- “The NHS reference sells itself”
US buyers rarely price NHS deployment as evidence. They want outcomes in a comparable US population, with US coding and US cost of care attached.
- “The US is one market”
Licensure, credentialling and payer enrolment are state-level. Every additional state adds its own timeline rather than sharing the previous one.
- “Referrals will behave the same way”
UK demand often arrives through a small number of institutional routes. US demand is fragmented across employers, plans, networks, brokers and direct consumers.
- “Pricing translates”
US price points can look generous until credentialling, billing, denials, no-show rates and acquisition costs are loaded into the unit economics.
- “We can run it from the UK”
Time zones, licensure and buyer expectations usually force a US-based operating spine earlier than the plan assumes.
The longer version, with what to replace each assumption with, is in 10 assumptions that break in the American market.
Build, buy or partner
Entry is not only a market question; it is a constraint question. If licences, credentialled clinicians or an existing referral base are what you are short of, acquisition or partnership buys the constraint. If the model itself is genuinely new, building is usually the only honest option. We compare the routes on total cash to a stable operating margin rather than headline cost — the framework is set out in build vs buy for UK and US expansion.
Where an acquisition is on the table, the operational diligence question follows immediately — operational due diligence covers how we test whether the asset can carry the growth case.
How engagements usually run
Most US entry work starts as a short discovery engagement to establish whether the opportunity is real and which route to test, then moves into a fuller growth and operations blueprint if the answer is yes. Some clients keep Ian involved on a fractional basis through execution. Indicative ranges and formats are on the engagements page.
Frequently asked questions
- What does a US healthcare market entry consultant actually do?
- The useful version of the role is not market research. It is helping you decide who your buyer is, which route to revenue you can realistically win, what the operating model has to look like to serve US patients, and in what order to spend money. Clarendum works on that decision with you and stays involved while the plan is executed.
- How long does it take a UK healthcare company to enter the US?
- For a cash-pay or employer-funded model with a light clinical footprint, a first paying customer inside six to nine months is realistic. Where clinician licensure, credentialling and payer enrolment are involved, twelve to twenty-four months per state group is a more honest planning assumption. The variable that moves the timeline most is whether you are contracting with payers.
- Is it better to go payer-contracted or cash-pay first in the US?
- Cash-pay and employer-funded routes are faster to validate and give you pricing freedom, but the addressable market is narrower and acquisition costs sit on you. Payer contracting unlocks volume but adds credentialling, enrolment, coding, claims and denials management — an operational function most UK entrants do not have. Many providers sequence: prove the model on cash-pay, then contract.
- Do I need a US entity and US clinicians?
- In almost all clinical delivery models, yes: care delivered to a US patient is generally provided by a clinician licensed in that patient's state. That reality shapes hiring, rotas, supervision and cost base far more than most UK plans assume. Corporate structure, tax and licensing specifics should be confirmed with US legal and tax advisers.
- How does Clarendum work with investors on US entry?
- Usually as an operator's second opinion: whether the entry plan in the deck can be delivered by this team, at this cost, on this timeline — and what the first hundred days after commitment should contain.
Ready to pressure-test your US expansion?
A short call is usually enough to establish whether your route to revenue is viable and what would have to be true to commit capital.